United Kingdom · Question · Written question
UIN 80347
Prescription Drugs
Introduced
23 November 2021
Last action
30 November 2021 · Answer
Status
Answered
Sponsors
—
Subjects
Discovery layer
Source updated
30 November 2021
Summary
To ask the Secretary of State for Health and Social Care, what discussions he has had with relevant stakeholders on reviewing prescription guidelines following the decision by the Competition and Markets Authority to fine Advanz for the inflation of the p
This text is taken from the official record. PoliticalRepo does not editorialize.
Timeline
23 November 2021
Written question
To ask the Secretary of State for Health and Social Care, what discussions he has had with relevant stakeholders on reviewing prescription guidelines following the decision by the Competition and Markets Authority to fine Advanz for the inflation of the p
Source: Commons
30 November 2021
Answer
We have had no discussions. NHS England and NHS Improvement’s guidance, ‘Items which should not routinely be prescribed in primary care: Guidance for CCGs’ identifies items which are clinically effective but where more cost-effective products are availabl...
Source: Written answer
Votes
No vote records are attached yet.
Versions
No version snapshots stored. Document URLs remain at the source.
Documents
No documents linked.
Sponsors
- · Department of Health and Social Care · Answering body
Related records
No cross-record relationships stored yet.
Sources
PoliticalRepo is an index and interpretation layer, not the authoritative legal source.
- Official source: https://questions-statements.parliament.uk/written-questions/detail/2021-11-23/80347
- Open data entity: https://questions-statements-api.parliament.uk/api/writtenquestions/questions/1381387
- uk · wq-1381387 · source updated 30 November 2021